摘要:美国联邦食品和药物管理局(FDA)前不久批准了诺华贵公司旗下一款用于治疗脊髓性肌萎缩(SMA)的基因疗法--Zolgensma的上市,其以超过210万美元(约合1452万人民币)的单价一跃成为全球市场上有史以来最昂贵的药物。
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社
热门期刊服务
Journal of Hydrodynamics Journal of Huazhong University of Science and Technology The Journal of China Universities of Posts and Telecommunications Journal of Genetics and Genomics Journal of Iron and Steel Research Journal of Systems Science and Complexity World Journal of Gastroenterology Journal of Computer Science and Technology Applied Mathematics:A Journal of Chinese Universities International Journal of Minerals Metallurgy and Materials International Journal of Mining Science and Technology Journal of Systems Science and Systems Engineering